Update on the issues of HIV vaccine development - PubMed (original) (raw)
Update on the issues of HIV vaccine development
B F Haynes et al. Ann Med. 1996 Feb.
Free article
Abstract
Major scientific obstacles blocking the development of a successful preventive HIV vaccine are the extraordinary variability of HIV, the lack of an exact animal model of HIV-induced AIDS, and the lack of understanding of the correlates of positive immunity to HIV. Current HIV vaccines containing the HIV gp120 envelope have been tested in phase I and II trials but they have had a major limitation of neutralizing only T-cell tropic laboratory-adapted HIV strains grown in T-cell lines, but not neutralizing HIV primary isolates. Phase III trials of monovalent HIV gp120 envelope vaccines are being planned in the US and Thailand, but concern has been raised that recombinant monovalent gp120 may not be an appropriate immunogen for an efficious HIV vaccine. Because the immune response is probably responsible for controlling the viral load in some long-term survivors of HIV infection, studies are now being carried out to induce similar immunity against a broad spectrum of strains of HIV primary isolates with targeted HIV experimental immunogens.
Similar articles
- A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR. Jones AT, et al. J Virol. 2018 Feb 12;92(5):e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1. J Virol. 2018. PMID: 29237847 Free PMC article. - Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX. Kim M, et al. AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67. doi: 10.1089/aid.2005.21.58. AIDS Res Hum Retroviruses. 2005. PMID: 15665645 - Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL, Robb ML, Kim JH. Excler JL, et al. Am J Prev Med. 2015 Dec;49(6 Suppl 4):S307-18. doi: 10.1016/j.amepre.2015.09.004. Am J Prev Med. 2015. PMID: 26590431 Review. - Bioorganic approaches towards HIV vaccine design.
Wang LX. Wang LX. Curr Pharm Des. 2003;9(22):1771-87. doi: 10.2174/1381612033454432. Curr Pharm Des. 2003. PMID: 12871196 Review.
Cited by
- Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M. Someya K, et al. J Virol. 2005 Feb;79(3):1452-62. doi: 10.1128/JVI.79.3.1452-1462.2005. J Virol. 2005. PMID: 15650171 Free PMC article. - Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX, Etemad-Moghadam B, Montefiori DC, Sun Y, Sodroski J, Scearce RM, Doms RW, Thomasch JR, Robinson S, Letvin NL, Haynes BF. Liao HX, et al. J Virol. 2000 Jan;74(1):254-63. doi: 10.1128/jvi.74.1.254-263.2000. J Virol. 2000. PMID: 10590113 Free PMC article. - A global theme issue: bibliography of references.
Winker MA. Winker MA. Emerg Infect Dis. 1996 Oct-Dec;2(4):365-72. doi: 10.3201/eid0204.960422. Emerg Infect Dis. 1996. PMID: 9011382 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources